Adverse Outcome Pathways holding the key to regulatory hurdles?

By Lucy Whitehouse

- Last updated on GMT

Following a successful in-cosmetics workshop on the regulatory issues facing the industry, Annelie Struessman of CONUSBAT, chair of the workshop, stopped off to give the Cosmetics Design team the low-down on what was discussed.

Currently an industry hot topic following the sweeping ban that came in last year, alternatives to animal testing were the key focus of the workshop, and Annelie noted that the general mood was one of concern.

We do not have a testing alternative available that is fully validated, so we do have a problem​,” Annelie confirmed.

What are we doing?​” She put this forward as the key question being asked by industry players. “For Europe it’s the question: what are we doing?​”

It's not all doom and gloom though: here, Annelie, who is CONUSBAT's technical and regulatory director, explains some promising developments on the cards at the moment, particularly noting that Adverse Outcome Pathways may hold the key to the regulatory question. 

Related topics: Regulation & Safety

Related news